New indication approved for asthma drug

Article

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

Merck received FDA approval for a new indication for montelukast 10 mg (Singulair). The medication can now be prescribed for exercise-induced bronchoconstriction (EIB) in patients 15 years and older [more].

According to the manufacturer, a single dose prevented EIB when taken two hours before exercise. Some patients benefited from the drug at 8.5 and 24 hours after administration, however some did not. Symptoms include shortness of breath, cough, wheeze, and chest tightness brought on by exercise. EIB affects a broad spectrum of patients with asthma.

Related Videos
Carissa Baker-Smith
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
© 2024 MJH Life Sciences

All rights reserved.